← Top stories
Policy● Neutral for Indian equities
Regulator mulls digital platform for drugmakers' test reports
The brief
- India’s drug regulator is developing a digital platform for consumers to view batch-level quality-test reports
- The platform could affect Indian drugmakers through greater public visibility of product quality tests
- Buy Aster DM Healthcare; target of Rs 910: Motilal Oswal
- Lupin receives USFDA tentative approval for Apixaban Oral Suspension 1.25 mg/mL
- Dr Reddy's shares gain over 1% after Nomura retains 'Buy'; Rs1,740 target, key biologics milestones ahead
- Shrikant Chouhan recommends buying Torrent Pharma, selling Bharti Airtel
- Morepen Laboratories submits first ANDA to USFDA for Sitagliptin Tablets
Digital tools for drug verification and quality reports
An explainer said the NHRC wants India's drugs regulator to create a national digital registry using unique QR codes and tracking tools to verify medicines and trace their movement. The regulator is also developing a digital platform for consumers to view batch-level quality-test reports.
Friday, 25 September
- Regulator mulls digital platform for drugmakers' test reports